Shares of Pharmasset (VRUS) shoot up 8.4% premarket after Morgan Stanley reiterates an...

|By:, SA News Editor

Shares of Pharmasset (VRUS) shoot up 8.4% premarket after Morgan Stanley reiterates an Overweight rating after taking in the results of a study on the firm's liver disease treatment. The company took a hit Friday, down 11.9%, after rival Inhibitex (INHX) hit a home run with positive data from its hepatitis C drug trial.